在非典型的阿尔茨海默氏症中改变了网络内部和网络之间的功能连接
Neha Atulkumar Singh1, Peter R Martin2, Jonathan Graff-Radford1
1Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA.
Brain communications
|July 12, 2023
概括
非典型的阿尔茨海默氏症,包括后皮层缩和逻辑开放性渐进性失语症,显示大脑网络连接受损. 与控制器相比,这些条件表现出与控制器相比,在网络内和网络之间功能连接的改变的明显模式.
科学领域:
- 神经科学是一个神经科学.
- 医疗成像医学成像
- 认知神经学 认知神经学
背景情况:
- 后皮层缩 (PCA) 和逻辑开放性渐进性失言症 (LPA) 是阿尔茨海默病 (AD) 的非典型表现.
- 之前的研究强调了这些表型中的功能网络中断,特别是在语言 (LPA) 和视觉 (PCA) 网络中.
- 在这些非典型的AD形式中,对网络内部和网络之间的连接差异的理解仍然有限.
研究的目的:
- 调查和比较PCA和LPA患者的网络内部和网络之间的功能连接.
- 为了确定异型阿尔茨海默病中大脑网络连接的表型特异性变化.
主要方法:
- 招募了144名PCA或LPA患者和健康对照.
- 使用结构性和静止状态功能性MRI (rs-fMRI) 来获取数据.
- 采用贝叶斯的层次线性模型,在多个大脑网络中进行voxel级和网络级连接分析.
主要成果:
- 在默认模式和传感器电机网络中,PCA和LPA都显示了网络内部连接的减少.
- LPA显示语言网络连接性降低;PCA显示视觉网络连接性降低.
- 观察到网络之间的连接变化,PCA显示视觉到语言连接减少,LPA显示语言到视觉连接减少.
结论:
- 非典型的阿尔茨海默氏病表型 (PCA和LPA) 具有在网络内部和网络之间的功能连接中显著的干扰的特点.
- 对于PCA (视觉网络) 和LPA (语言网络) 存在不同的连接模式,强调了表型特定的神经生物学基础.
- 这些发现有助于更好地了解非典型阿尔茨海默氏症表现背后的多种神经机制.
更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.0K
09:01A Method for Investigating Age-related Differences in the Functional Connectivity of Cognitive Control Networks Associated with Dimensional Change Card Sort Performance
Published on: May 7, 2014
10.2K
相关概念视频
Alzheimer's Disease: Overview
525
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
525
Alzheimer's Disease: Treatment
219
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
219
